PE20181376A1 - Analogos del egf(a) con sustituyentes de acidos grasos - Google Patents

Analogos del egf(a) con sustituyentes de acidos grasos

Info

Publication number
PE20181376A1
PE20181376A1 PE2018001257A PE2018001257A PE20181376A1 PE 20181376 A1 PE20181376 A1 PE 20181376A1 PE 2018001257 A PE2018001257 A PE 2018001257A PE 2018001257 A PE2018001257 A PE 2018001257A PE 20181376 A1 PE20181376 A1 PE 20181376A1
Authority
PE
Peru
Prior art keywords
egf
fatty acid
bond
analogs
yglu
Prior art date
Application number
PE2018001257A
Other languages
English (en)
Spanish (es)
Inventor
Jianhe Chen
Jesper F Lau
Janos Tibor Kodra
Birgit Wieczorek
Lars Linderoth
Henning Thøgersen
Salka Elbøl Rasmussen
Patrick William Garibay
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PE20181376A1 publication Critical patent/PE20181376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PE2018001257A 2016-01-13 2017-01-13 Analogos del egf(a) con sustituyentes de acidos grasos PE20181376A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016070791 2016-01-13
CN2016076580 2016-03-17
EP16195965 2016-10-27

Publications (1)

Publication Number Publication Date
PE20181376A1 true PE20181376A1 (es) 2018-09-05

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001257A PE20181376A1 (es) 2016-01-13 2017-01-13 Analogos del egf(a) con sustituyentes de acidos grasos

Country Status (26)

Country Link
US (2) US10822385B2 (2)
EP (1) EP3402811B1 (2)
JP (2) JP6797926B2 (2)
KR (1) KR102417487B1 (2)
CN (1) CN108473550B (2)
AU (1) AU2017207862B2 (2)
BR (1) BR112018013820A2 (2)
CA (1) CA3010756A1 (2)
CL (1) CL2018001868A1 (2)
CO (1) CO2018007440A2 (2)
DK (1) DK3402811T3 (2)
ES (1) ES2916998T3 (2)
HR (1) HRP20220720T1 (2)
HU (1) HUE058647T2 (2)
IL (1) IL260043A (2)
LT (1) LT3402811T (2)
MX (1) MX2018008681A (2)
MY (1) MY195199A (2)
PE (1) PE20181376A1 (2)
PH (1) PH12018501502A1 (2)
PL (1) PL3402811T3 (2)
RS (1) RS63298B1 (2)
RU (1) RU2747877C2 (2)
SA (1) SA518391996B1 (2)
SI (1) SI3402811T1 (2)
WO (1) WO2017121850A1 (2)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
CA3011176C (en) 2016-01-13 2023-09-19 Grunenthal Gmbh 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CA3011180A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
SI3402784T1 (sl) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
MA49617A (fr) * 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
US11358994B2 (en) * 2017-07-27 2022-06-14 Saint Louis University Fatty acid modified human epidermal growth factor
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
WO2020070276A1 (en) 2018-10-05 2020-04-09 Novo Nordisk A/S Bifunctional compounds comprising insulin peptides and egf(a) peptides
CA3131997A1 (en) 2019-03-22 2020-10-01 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
AU2020326265A1 (en) 2019-08-07 2022-02-03 Novo Nordisk A/S Solid compositions comprising an EGF(A) derivative and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114641275A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含pcsk9抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
EP4076492A4 (en) 2019-12-20 2024-01-17 Merck Sharp & Dohme LLC PCSK9 ANTAGONIST COMPOUNDS
JP2024527488A (ja) 2021-07-02 2024-07-25 スリーエム イノベイティブ プロパティズ カンパニー 落下防止安全装置と連動される空中リフト
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
MX2010011499A (es) * 2008-04-23 2010-11-12 Amgen Inc Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN103052900A (zh) 2010-08-02 2013-04-17 日本电气株式会社 偏振器和发光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
JP2014510516A (ja) 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
WO2012177741A1 (en) * 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use
AU2012311484B2 (en) * 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US20140357838A1 (en) * 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
TW201420606A (zh) 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
JP2015533483A (ja) 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
EP2986313B1 (en) * 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2935285A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9-glp-1 fusions and methods for use
US10570184B2 (en) * 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
US20180207223A1 (en) * 2015-03-19 2018-07-26 Institut De Cardiologie De Montreal Pcsk9 inhibitory polypolypeptides and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées

Also Published As

Publication number Publication date
CN108473550A (zh) 2018-08-31
AU2017207862A1 (en) 2018-07-05
DK3402811T3 (da) 2022-06-13
US20200407409A1 (en) 2020-12-31
JP6797926B2 (ja) 2020-12-09
WO2017121850A1 (en) 2017-07-20
PL3402811T3 (pl) 2022-07-11
EP3402811A1 (en) 2018-11-21
JP2019505521A (ja) 2019-02-28
EP3402811B1 (en) 2022-03-30
KR20180100177A (ko) 2018-09-07
RS63298B1 (sr) 2022-07-29
CN108473550B (zh) 2022-11-22
PH12018501502A1 (en) 2019-03-25
US10822385B2 (en) 2020-11-03
US20190016768A1 (en) 2019-01-17
MY195199A (en) 2023-01-11
KR102417487B1 (ko) 2022-07-06
CO2018007440A2 (es) 2018-09-28
RU2018127882A3 (2) 2020-06-19
IL260043A (en) 2018-07-31
RU2018127882A (ru) 2020-02-13
MX2018008681A (es) 2018-09-17
SI3402811T1 (sl) 2022-06-30
SA518391996B1 (ar) 2021-07-14
HRP20220720T1 (hr) 2022-09-30
LT3402811T (lt) 2022-06-10
ES2916998T3 (es) 2022-07-06
HUE058647T2 (hu) 2022-09-28
CA3010756A1 (en) 2017-07-20
BR112018013820A2 (pt) 2018-12-11
RU2747877C2 (ru) 2021-05-17
CL2018001868A1 (es) 2018-08-31
AU2017207862B2 (en) 2020-12-17
JP2021035989A (ja) 2021-03-04

Similar Documents

Publication Publication Date Title
PE20181376A1 (es) Analogos del egf(a) con sustituyentes de acidos grasos
CU24448B1 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
CL2020002224A1 (es) Agonistas de fenilpirrolidinona del receptor 2 de formil péptido
CU20200046A7 (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
PE20220488A1 (es) Variantes del cnp y sus conjugados
ECSP22010228A (es) Conjugados peptídicos de citotoxinas como terapéuticos
CU20190069A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr)
MX392554B (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5.
MX381474B (es) Compuesto que tiene olor de lirio del valle.
CU20190067A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr)
BR112019008453A2 (pt) composições de polímero com plastificante de pbsa
DOP2019000047A (es) Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarias o inflamatorias o cánceres
AR069437A1 (es) Bisfosfonatos de alquilo de 2 a 5 atomos de carbono - imidazol
PE20181355A1 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
MX386098B (es) Analogos metabolicamente robustos de cyp-eicosanoides para el tratamiento de enfermedades cardiacas.
CO2021011721A2 (es) Mezcla de subproducto de hidroformilación de octeno y diésel, queroseno o c8-c20 olefinas como recolectores
MX2026001623A (es) Composiciones azeotropicas o similares a azeotropo de 3,3,3-trifluoropropino y agua
EA201992226A1 (ru) Агонисты npra, композиции и их использование
JOP20250299A1 (ar) المركبات السبيرو ماكروسيكلية الناهضة لمستقبِل الأوركسين 2
EA201792640A1 (ru) Устойчивые к действию протеазы липидированные аналоги glp-1
AR125039A2 (es) Un compuesto derivado de indeno-amida
AR122141A1 (es) Inhibidor de trka
BR112021026061A2 (pt) Método para o tratamento de uma composição que compreende vanilina natural